Injection of autoantigens in IFA has been one of the most effective ways of preventing experimental, T cell-mediated, autoimmune disease in mice. The mechanism that underlies this protection has, however, remained controversial, with clonal deletion, induction of suppressor cells or of type 2 immunity being implicated at one time or another. Using high resolution enzyme-linked immunospot (ELISPOT) analysis, we have revisited this paradigm. As models of autoimmunity against sequestered and readily accessible autoantigens, we studied experimental allergic encephalomyelitis, induced by myelin oligodendrocyte glycoprotein, proteolipid protein, myelin basic protein, and renal tubular Ag-induced interstitial nephritis. We showed that the injection of each of these Ags in IFA was immunogenic and CD4 memory cells producing IL-2, IL-4, and IL-5, but essentially no IFN-␥. T he consensus on the primary mechanisms that prevent harmful autoimmune reactions has oscillated over the last few decades between passive tolerance resulting from the clonal deletion/inactivation of autoreactive T cells and active tolerance mediated by regulatory T cells. Tolerance induced by the injection of autoantigens mixed in IFA (1, 2) was initially thought to be mediated by regulatory/suppressor cells because resistance to subsequent induction of experimental allergic encephalomyelitis (EAE) 4 could be adoptively transferred to naive recipients (3-6). When the propounded suppressor cell models came under scrutiny (7), IFA-induced tolerance was reexamined. It was then shown that mice preinjected with Ag in IFA failed to generate proliferative (8, 9) and IL-2 recall responses (10) in their draining LNs when they were reimmunized with the same Ag in CFA. This lack of responsiveness seemed to occur in the absence of detectable regulatory cells in the draining LNs (8, 9). Direct visualization studies using adoptively transferred TCR transgenic cells showed that the Ag-specific cells disappeared from the draining LNs under these conditions (11). Moreover, the generation of T cell hybridomas from draining LNs of wild-type mice suggested that the residual cells lacked high affinity Ag-specific T cell clones following IFA preinjection (12). These types of data have led to the view that IFA injections induce tolerance via clonal deletion. Additionally, in favor of this interpretation is the prevalent infectious nonself/ noninfectious self model of immunogenicity (13, 14) , according to which the induction of a T cell response requires immunogenic Ags to be encountered in association with microbial products (13, 14) . Unlike Ag injections in CFA (mycobacterial proteins in mineral oil), injections of Ag in IFA (mineral oil only) were thought to be prone to induce tolerance because such water:oil emulsions, by serving as excellent Ag depots that last for months (15, 16), provide the first signal without the bacterial products present to engage the second signal.
T he consensus on the primary mechanisms that prevent harmful autoimmune reactions has oscillated over the last few decades between passive tolerance resulting from the clonal deletion/inactivation of autoreactive T cells and active tolerance mediated by regulatory T cells. Tolerance induced by the injection of autoantigens mixed in IFA (1, 2) was initially thought to be mediated by regulatory/suppressor cells because resistance to subsequent induction of experimental allergic encephalomyelitis (EAE) 4 could be adoptively transferred to naive recipients (3) (4) (5) (6) . When the propounded suppressor cell models came under scrutiny (7), IFA-induced tolerance was reexamined. It was then shown that mice preinjected with Ag in IFA failed to generate proliferative (8, 9) and IL-2 recall responses (10) in their draining LNs when they were reimmunized with the same Ag in CFA. This lack of responsiveness seemed to occur in the absence of detectable regulatory cells in the draining LNs (8, 9) . Direct visualization studies using adoptively transferred TCR transgenic cells showed that the Ag-specific cells disappeared from the draining LNs under these conditions (11) . Moreover, the generation of T cell hybridomas from draining LNs of wild-type mice suggested that the residual cells lacked high affinity Ag-specific T cell clones following IFA preinjection (12) . These types of data have led to the view that IFA injections induce tolerance via clonal deletion. Additionally, in favor of this interpretation is the prevalent infectious nonself/ noninfectious self model of immunogenicity (13, 14) , according to which the induction of a T cell response requires immunogenic Ags to be encountered in association with microbial products (13, 14) . Unlike Ag injections in CFA (mycobacterial proteins in mineral oil), injections of Ag in IFA (mineral oil only) were thought to be prone to induce tolerance because such water:oil emulsions, by serving as excellent Ag depots that last for months (15, 16) , provide the first signal without the bacterial products present to engage the second signal.
Despite these apparently convincing arguments for Ag:IFA injections triggering clonal deletion, the issue remains controversial in that there are recent publications implicating anergy (17) and induction of an active type 2 immune response (18, 19) as being operative under these conditions. The controversy derives in part because it has been challenging to define the impact of Ag:IFA injections on the specific T cells in normal (nontransgenic) mice, in which the naturally occurring low frequencies of precursor cells have stymied direct measurements. Recently, a new generation of cytokine ELISPOT assays has emerged (20) that permit one to study Ag-specific T cells directly ex vivo at single cell resolution and that facilitate the direct visualization of Ag-induced cytokine produced by even a single Ag-specific T cell in a million bystander cells (20) . Enabled by these assays, we set out to revisit the effects of Ag:IFA injections. We previously showed that IFA injections of foreign Ag are prone to induce CD4 cells that produce IL-4 and IL-5, but not IFN-␥, and IgG1 and IgE, but not IgG2a Ab responses, as is consistent with a polarized type 2 immune response (19) . These experiments also showed that the induced CD4 memory cells were L-selectin negative, and that this lack of LN-homing receptor expression accounted for the aforementioned deficient LN responses (8, 9, 11) ; after the same Ag was reinjected, the memory cells were not recruited to the LN, but were present in the spleen (18) . These data explained why clonal deletion was implicated in the IFA-induced tolerance when LNs were the only organs examined. With all foreign protein Ag, in all mouse strains studied, we found IFA injections to induce this polarized, type 2 immunity when spleen cells were tested (19) .
T cell responses to autoantigens, however, might differ fundamentally from those generated against foreign Ags. Autoantigens frequently delete the high affinity end of the autoreactive T cell repertoire (21, 22) . This also holds for MBP (23) and possibly for other neuroantigens that until recently were thought to be sequestered behind the blood brain barrier (BBB). Unlike the response to foreign Ags, therefore, the T cell response to autoantigens might comprise primarily low affinity clones (24) . Because T cell affinity has been implicated in defining cytokine differentiation along the type 1/type 2 pathways (25, 26) , the outcome of autoantigen:IFA injections might differ fundamentally from inoculations of foreign Ag in IFA. Along the same lines, there is emerging evidence that the autoreactive T cell repertoire is not necessarily naive (as is the case for foreign Ags), but instead can consist at least partially of T cells preactivated by exposure to endogenous Ag (27) . Unlike naive cells, preactivated/memory cells are committed to a particular cytokine-secreting lineage (28, 29) and, thus, the polarizing effects of adjuvants may not easily redirect their type 1/type 2 differentiation status. It therefore remains to be determined whether autoantigen:IFA injections have the same immunizing/type 2-polarizing effects as seem to be the rule for injections of foreign Ags.
It was initially accepted that Th2 cells could have a regulatory function that suppresses Th1 cell-mediated effector functions, a hypothesis with the potential to explain the previously observed suppressor cell phenomena (30 -32) . This view has more recently come under significant scrutiny. It was shown, for example, that the cotransfer of autoreactive, Th2-polarized, putative regulatory T cells with Th1-polarized effector T cells did not prevent or ameliorate autoimmune pathology, even when the Th2 cells were in marked excess over the Th1 cells (33) (34) (35) . To the contrary, such adoptive transfers indicated that the autoreactive Th2 cells could themselves induce inflammatory responses in the target organ, thus contributing to tissue destruction. Although this pathology was seen after injecting large numbers of Th2 cells preactivated in vitro and primarily in immune-deficient recipients, it remains controversial whether a type 2 response endogenously developing in an immunocompetent host can be similarly pathogenic (particularly as it pertains to violations of self tolerance following infections or vaccinations/active immunotherapy). Similarly, it is unclear whether and under which conditions this type 2 violation of self tolerance can protect from autoimmune diseases and how to reconcile the regulatory suppressor qualities of Th2 cells in such models (36 -38) .
The classic experiments on IFA-induced tolerance were done with MBP, an intracellular protein buried within the myelin sheath, where it is inaccessible to autoantibodies. Additionally, in this EAE model, the BBB may limit the access of the induced autoantibodies to the CNS in the absence of preexisting, activated T cells (39, 40) . This model, therefore, is prone to underestimation of the potential hazards of autoantibodies induced along with Th2 cells. In contrast, MOG is a cell surface protein in the CNS, and the development of aggressive, demyelinating EAE in rats has been tied to the presence of anti-MOG Abs in addition to autoreactive T cells (41) (42) (43) . Using MOG-induced EAE in marmoset monkeys, it was noted that the secondary injection of soluble MOG into MOG: CFA-preimmunized animals caused a Th2 shift in the T cell response, but eventually resulted in a delayed and more severe form of EAE (44) . These and other experiments (45) , including induction of EAE in some rat strains using neuroantigen/IFA injections (46) , have raised significant concern regarding the potential pathogenicity of therapies aimed at exploiting active/regulatory immune mechanisms for treatment of autoimmune diseases. These concerns might be even more substantial when the extracellular target Ags used are not protected from autoantibodies by anatomic barriers such as the BBB.
In an effort to address these issues, we revisited three models of EAE (mediated by injections of MBP, PLP, and MOG, respectively) and a related model of murine interstitial nephritis, antitubular basement membrane (␣TBM) disease (47) (48) (49) . Like EAE, ␣TBM disease is elicited by immunization with a tissue-specific autoantigen (renal tubular Ag, RTA) in CFA, and injection of RTA with IFA has been reported to prevent the disease (50) . In this manner, we studied autoimmunity directed toward an immuneprivileged organ, the CNS, and toward a nonimmune-privileged target organ, the kidney. Although the BBB might make the CNS unique with respect to access by T cells and Abs, the kidney is an organ whose anatomy makes it highly accessible to Abs and immune cells. Moreover, while the immune-privileged state of the CNS tends to cause entering T cells to undergo apoptosis (51-53), this does not apply to the kidney. Therefore, although EAE is the best studied and most commonly used model of experimentally induced autoimmune disease, it is also a unique autoimmune model. The inclusion of ␣TBM disease was thus used in an effort to understand more broadly pathogenic and protective qualities of the different autoimmune response types.
Materials and Methods

Animals, Ags, and treatments
Male and female SJL (H-2 s ), B10.PL (H-2 u ), and C57.BL/6 (H-2 b ) mice, age 6 -8 wk, were purchased from The Jackson Laboratory (Bar Harbor, ME), and maintained under specific pathogen-free conditions in the animal facilities of Case Western Reserve University and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center (Cleveland, OH). RTA and MBP were prepared in our laboratory, as described (47, 54) . The nonglycosylated recombinant protein corresponding to the extracellular domain of rat MOG (aa 1-125) was expressed in the Escherichia coli strain DH5-␣ and purified to homogeneity, as previously described (55) . The PLP peptide (PLPp) 139 -151 (H-HCLGKWLGHPDKF-OH) was synthesized and purchased from Princeton Biomolecules (Columbus, OH). IFA was purchased from Life Technologies (Grand Island, NY), and CFA was made by mixing Mycobacterium tuberculosis H37RA (Difco Laboratories, Detroit, MI) at 2.5 mg/ml into IFA. For inducing autoimmune diseases, either autoantigens or peptides were mixed with CFA to yield emulsions at previously established maximum pathogenic concentrations, 1 mg/ml for MBP, MOG, and PLP(139 -151), and 4 mg/ml for RTA. Of this emulsion, 50 l was injected once, s.c. at four sites on the flank. Pertussis toxin (200 ng; List Biological, Campbell, CA) was injected i.p. in 500 l saline, at the time of the CFA immunization and repeated 24 h later. Injections of autoantigens in IFA emulsions involved the same dose of Ags as specified above for their inoculation in CFA, administered with a single 200 l i.p. injection. Starting from day 5 after injections of neuroantigens, the mice were assessed daily for the development of paralytic symptoms, and the severity of disease was recorded according to the standard scale: grade 1, floppy tail; grade 2, hind leg weakness; grade 3, full hind leg paralysis; grade 4, quadriplegia; grade 5, death.
Organ harvest, histologic analysis, and detection of in situ bound Ab
Kidneys and the CNS were harvested when the animals were sacrificed. Portions of each organ were fixed in 10% Formalin, and paraffin sections were made and stained with hematoxylin and eosin (portions of each harvested organ were also frozen in OCT compound for immunofluorescence studies of Ab staining; see below). The presence of infiltrating leukocytes was determined in a semiquantitative manner by a trained investigator, blinded to the experimental group. Disease scores for interstitial nephritis were defined as follows. Grade 0, normal kidney; grade 0.5, rare focal mononuclear cell infiltration; grade 1, mononuclear cell infiltration of the interstitium of Ͻ10% of the renal cortex; grade 2, mononuclear cell infiltration of the interstitium of Ͼ10% Ͻ50% of the renal cortex; grade 3, mononuclear cell infiltration of the interstitium of Ͼ50% of the renal cortex with tubular drop-out and interstitial fibrosis (47, 48) . Standard histologic scoring of brain inflammation in EAE was used (23, 34) . For detection of in situ bound Ab, frozen sections of kidney or brain tissue from naive or immunized mice were washed three times in PBS, blocked for 30 min with 1% BSA, stained with FITC-conjugated goat anti-mouse Ig or control Ig (1/50 dilution in PBS/0.1% BSA; PharMingen, San Diego, CA) for 30 min, and washed three times more in PBS. The dried sections were examined under an immunofluorescent microscope at 450 nm and photographed.
ELISA assays for detecting autoantigen-specific serum Ab
ELISA plates (Nunc Immunoplate; Fisher Scientific, Pittsburgh, PA) were coated overnight with 100 l of 10 mg/ml RTA, MBP, or MOG at 4°C. The plates were washed three times with PBST, blocked for 1 h with 0.1% gelatin, both in PBS with 0.025% Tween (PBST) at room temperature, and washed again. Serial 3-fold dilutions of serum, starting at 1/500 in RPMI, were added in duplicate to the plate and placed at 4°C overnight. After washing with PBST, three times, the detection Abs were added. Affinitypurified goat anti-mouse IgG (HϩL) from Southern Biotechnology Associates (Birmingham, AL) was used to detect total Ig; the isotype-specific Abs used to detect IgG1 and IgG2a were also from Southern Biotechnology Associates. p-Nitrophenylphosphate (PNPP; Research Organics, Cleveland, OH) was used for the development of the colorimetric reaction. After incubating for 4 h at room temperature, the plates were again washed three times in PBST, and streptavidin-alkaline phosphatase (1/2000 dilution; Dako, Carpinteria, CA) was added for 1 h. The plates were developed with a PNPP substrate, and the OD was read at 405 nm.
Cell purification and adoptive transfers
Single cell suspensions were prepared from spleens, and these were tested either as bulk populations or as purified cell fractions, as specified. Subpopulations of T cells were isolated using commercially available murine T cell isolation columns (R&D Systems, Minneapolis, MN), following the instructions supplied by the manufacturer. Resultant cells were washed in HBSS, counted by trypan blue exclusion, and resuspended at appropriate concentrations for use in the various assays. Purity was confirmed by FACS analysis using FITC-conjugated Abs (PharMingen). The columns routinely yielded Ͼ96% purity for CD4 ϩ T cells. For preparation of APC, spleen cells from naive mice were incubated with mitomycin C (Boehringer Mannheim Biochemicals, Indianapolis, IN) at 50 g/ml in PBS for 20 min at 37°C, followed by three washes in HBSS. For adoptive transfers, 80 ϫ 10 6 T cells from spleens of immunized animals were injected, i.p., per recipient. Where indicated, these T cells have been preactivated by the respective Ag for 3 days before injection.
ELISPOT assays and ELISPOT image analysis
ImmunoSpot M200 plates (Cellular Technology, Cleveland, OH) were coated overnight with the capture Abs in sterile PBS. R46A4, at 4 g/ml (isolated and purified from hybridoma), was used for IFN-␥; JES6-1A12, 3 g/ml (PharMingen), for IL-2; 11B11, at 2 g/ml (isolated and purified from hybridoma), was used for IL-4; and TRFK5, at 5 g/ml (isolated and purified from hybridoma), was used for IL-5. The plates were blocked for 1 h with sterile 1% BSA in PBS and washed three times with sterile PBS. Spleen cells (10 6 per well) or purified T cells (5 ϫ 10 5 /well, with the same number of mitomycin C-treated syngeneic splenic APC) were plated in HL-1 medium (BioWhittaker, Walkersville, MD) and Ag or peptides at 100 g/ml, in triplicate wells. In select experiments, cells and Ags were titrated. The plates were incubated at 37°C, 7% CO 2 for 24 h (IFN-␥ and IL-2) or for 48 h (IL-4, IL-5, and two-color assays). After washing three times with PBS, followed by three times with PBS-0.025% Tween, detection Abs were added and plates were incubated overnight at 4°C. XMG1.2-HRP (produced in our laboratory) was used for IFN-␥, rat anti-mouse IL-4-biotin (BVD6-24G2; PharMingen) was used for IL-4, rat anti-mouse IL-2-biotin (JES6-5H4; PharMingen) was used for IL-2, and biotinylated TRFK4 (PharMingen) was used for IL-5. The plates were then washed three times in PBST. Streptavidin-HRP (Dako) was added at 1/2000 dilution in PBST as a third reagent for IL-2, IL-4, and IL-5 for 2 h, followed by three washes in PBS. The solution used to develop the plates consisted of 800 l AEC (Pierce, Rockford, IL; 1 g dissolved in 100 ml dimethyl formamide) mixed in 24 ml 0.1 M sodium acetate, pH 5, plus 12 ml H 2 O 2 ; 200 l was added per well.
For two-color ELISPOT assays (20) , the plates were coated simultaneously with two capture Abs, and the two detection Abs were added simultaneously as well. The following coating mAbs were used for twocolor IL-4 and IL-5 detection: BVD4-1D11 (2 g/ml), TRFK5 (5 g/ml). The combinations of detection Abs for the IL-4:IL-5 assays were: BVD4-24G2-biotin:TRFK4-HRP. HRP labeling of Abs was performed according to the standard method. The detection Ab concentrations were as follows: BVD4-24G2-biotin (2.5 g/ml), TRFK4-HRP (2 g/ml). For the biotinylated detection mAbs, the streptavidin-AP conjugate (Dako) was added (at 1/2000 dilution), incubated for 2 h at room temperature, and removed by washing twice with PBST and twice with PBS. The NBT/BCIP substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added first, then, after washing twice with PBS, the AEC substrate was added and left for 15-30 min for NBT/BCIP and 20 -40 min for AEC. The resulting spots were counted on an ImmunoSpot Series 1 Analyzer (Cellular Technology). For single-color ELISPOT, digitized images were analyzed for the presence of areas in which color density exceeds the background by a factor set on the basis of the comparison of control (containing T cells and APC without Ag) and experimental wells (containing Ag). After separating spots that touch or partially overlap, additional criteria of spot size and circularity are applied to gate out speckles and noise caused by spontaneous substrate precipitation and nonspecific Ab binding. Objects that do not meet these criteria are ignored, and areas that meet them are recognized as spots, counted, and highlighted. Two-color ELISPOT image analysis follows the same principles, except that the image analyzer detects red, blue, and double-colored spots separately by using three different color factors. When the blue is active, single-color blue and all double-positive spots (which have blue as a part of their color composition) are detected. Similarly, when red is active, only red single-color and double-color spots are detected. Each color factor is set in RGB (red, green, blue) mode and consists of three numbers reflecting the color intensity in red, blue, and green channels. The red and blue factors are set by using spots from single-color assays. The double-color factor is a mathematical intersection of the two single-color factors.
Results
Injection of autoantigen in CFA, but not in IFA, induces organ-specific pathology
As differences in mouse colonies and housing conditions might influence Th1/Th2 T cell differentiation and its subsequent autoimmune consequences, we first sought to establish the outcomes of autoantigen injections on the phenotypic expression of autoimmune disease. Specifically, we sought to determine whether injection with the CNS autoantigens MBP, PLPp, and MOG or the kidney autoantigen RTA mixed in IFA would induce clinical or histological evidence of target-organ pathology as compared with the classic CFA injections that have been the gold standard for inducing autoimmune disease. Table I summarizes the results. When susceptible mice were immunized with autoantigen mixed in CFA, 88 -100% of the animals developed clinical and/or histologic manifestations of autoimmune disease. The effects were target organ specific in that mice injected with either MBP or PLP did not develop detectable renal pathology, and RTA-injected mice did not show clinical or histologic evidence of CNS pathology (not shown).
In contrast, injections of neuroantigens mixed with IFA did not produce either clinical or histologic evidence of CNS pathology, and injections of RTA:IFA did not induce pathological changes in the kidney. Histologic sections of CNS or kidney tissue from Ag: IFA-injected animals were indistinguishable from those of naive mice, even up to 24 wk after the initial injection. We specifically did not see any evidence of eosinophilic infiltration that might be associated with type 2 immune responses (33) (34) (35) . In our hands, therefore, the classic CFA/IFA paradigm holds with respect to disease induction for three models of EAE and for ␣TBM disease: immunization in CFA induces autoimmune disease, and injection in IFA does not.
Induction of type 1 and type 2 cytokine signatures following injection of autoantigen in CFA and in IFA
The detection of low frequency cytokine-producing T cells has been challenging, particularly for type 2 cytokines in which the addition of receptor-blocking Abs may be required to detect them using standard ELISAs (56, 57) . To avoid loss of signal in supernatants due to dilution or receptor uptake, we measured cytokine production at single cell resolution with ELISPOT assays (20) . As shown in Fig. 1A , spleen cells from RTA:IFA-injected mice produced 20 -100/million RTA-specific IL-2, IL-4, and IL-5 spots in the presence of RTA over medium control. These RTA:IFA-injected mice did not produce any IFN-␥ in the recall response. The cytokine responses bore features of immunologic memory because naive mice did not produce cytokines when challenged with RTA, and RTA-injected mice did not respond to any of the neuroantigens (data not shown). Overall, similar type 2 polarization was seen when MBP, PLPp, and MOG were injected with IFA (Fig. 1,  B, C, and D) . Recall responses characterized by the production of IL-2, IL-4, and IL-5 in the absence of IFN-␥ could be specifically detected to the injected Ags. There were considerable variations noted, however, in the production of the individual cytokines, depending on which autoantigen was tested. Injections of MOG:IFA, for example, reproducibly led to IL-4 but not IL-5 production, while both cytokines were prevalent after injection of MBP, PLPp, and RTA. Moreover, we found that all of the cytokines induced by IFA immunization with these autoantigens were produced by CD4 cells (not shown), analogous to our previously reported findings for IFA immunizations using foreign Ags (19, 23, 47) .
Autoantigen:CFA-immunized mice showed specific IFN-␥ and IL-2 recall responses in comparable frequencies to the IL-4 and IL-5 response in IFA-injected mice (Fig. 1, A-D) , and cell separation showed that this response was also derived from CD4 T cells (not shown). In contrast to the IFA-injected animals, however, these mice did not produce IL-5, although IL-4 recall responses were detectable after immunization with some of the autoantigens. Overall, the induction of IFN-␥-producing memory cells was a constant feature of all CFA immunizations, while the absence of such IFN-␥-producing cells characterized all injections in IFA. IL-5, in contrast, was seen with most of the IFA injections (MOG being the only exception that we noted), yet was completely absent after CFA immunizations. Injections in IFA, therefore, were found to induce CD4 T cell immunity, albeit of different cytokine signatures than immunity induced by CFA injection. The frequencies of memory cells induced by IFA injection were similar to those following the disease-inducing CFA immunizations. Unlike the CFA immunizations, however, they occurred without signs of autoimmune pathology.
Type 2 cytokine signature in the absence of Th2 cells
The dissociated expression of IL-4 and IL-5 after MOG:IFA injection, and the often discordant frequencies of memory cells producing IL-4 and IL-5 induced by the other autoantigens prompted us to study the coexpression of these cytokines by individual cells. Using single cell resolution, two-color ELISPOT assays (20) , we found that IL-4 and IL-5 were, in fact, produced by different CD4 cells and that the number of cells coexpressing both cytokines was Ͻ5% of the total (Fig. 2) . Moreover, IL-2 was produced by the IFA-induced memory cells (which occurred in the absence of IFN-␥ production; Fig. 1 ), and this IL-2 was found to be secreted by different CD4 memory cells than IL-5 (data not shown). These 
Injection of autoantigen in IFA results in an IgG1 autoantibody response and organ-specific autoantibody deposition
Although autoantigen-specific IgG2a Abs were virtually absent in autoantigen:IFA-injected mice, these animals developed high titers of specific IgG1 Abs (Fig. 3) . In contrast, specific IgG2a was detectable at high titers in the serum of animals injected with autoantigens in CFA (Fig. 3) . As murine IgG2a Ab production depends upon the presence of IFN-␥-producing memory cells to provide T cell help for Ig class switching (58), the detection of this Ab isotype after CFA (but not IFA) injection matches well with the detected cytokine profiles of the memory cells themselves (Fig. 1) . Similarly, the presence of IgG1 Abs after both CFA and IFA immunization is consistent with the cytokine data, in that IgG1 Ig class switching depends upon IL-2 and IL-4 (59, 60). Moreover, this isotype may be less discriminatory for different immune response types because the IgG1 locus lies upstream from the more discriminatory IgG2a or IgE loci. Two of the autoantigens tested, MOG and RTA, are cell surface proteins. To test whether the anti-MOG and anti-RTA Abs detected in the sera of IFA-injected mice actually bind to their respective autoantigens in vivo, we stained the kidneys and the CNS of such mice with anti-IgG1 Abs. As shown in Fig. 4 , kidneys harvested from animals 3 wk after immunization with RTA:IFA FIGURE 1. Injection of autoantigen in IFA primes a type 2 cytokine recall response. Ag-induced cytokine recall responses were measured by ELISPOT assays testing spleen cells isolated 3 wk after injection of the autoantigen mixed in CFA (F) or IFA (E). A, RTA-specific responses in SJL mice. B, MBP-specific responses in B10.PL mice. C, PLPp-specific responses in SJL mice. D, MOG-specific responses in C57BL/6 mice. Each data point represents a single mouse. Shown is the mean number of spots counted by computer-assisted image analysis in two to three replicate wells (Ͻ15% variability between wells) after subtracting spontaneous production in wells with medium alone (Ͻ5 spots per well for IFN-␥, IL-2, and IL-5; Ͻ30 spots per well for IL-4). Specificity controls in all combinations, e.g., the testing for RTA-induced spot formation in mice immunized with MBP, MOG, or PLPp, gave results equal to medium control wells (not shown). showed staining of tubular basement membranes. Similarly, the brains of MOG:IFA-immunized mice stained positively for deposited IgG1. Notably, this autoantibody deposition was detectable in the absence of inflammatory cellular infiltration of the target organs (as assessed by hematoxylin and eosin) or clinical manifestations of disease for up to 6 mo following the immunization. Brains and kidneys from naive or control immunized mice did not bind the anti-IgG1 (or the isotype control) Ab. The data demonstrate that IFA injections did induce an actual humoral autoimmune response that entails specific autoantibody deposition in target organs. Yet, this violation of self tolerance occurred in the complete absence of detectable pathologic consequences.
Exhaustion of uncommitted precursor cells in IFA-preinjected, protected hosts
To test whether the previously reported IFA-induced protection also applies to our studies, in which autoimmune responses and not immunologic tolerance were clearly induced, we first injected mice with autoantigen:IFA, then with the disease-inducing autoantigen: CFA regimen. As shown in Table II, mice that were preinjected with IFA plus saline (or control Ags) developed organ-specific autoimmune disease of a severity corresponding to the score of mice that were not preinjected. In contrast, mice preinjected with RTA or MBP in IFA were largely protected from developing ␣TBM disease or EAE, respectively. Pretreatment of SJL mice with PLPp:IFA reduced the severity of subsequent EAE in all animals, and fully protected 20% of the animals compared with controls (Table II) . In all three models tested, the type 2 immunity induced with IFA injection was therefore associated with disease protection. Although the data seem to be consistent with the classic interpretation of Th2 cells inhibiting Th1 cell-mediated pathology, we used the high resolution ELISPOT assay to characterize directly the autoantigen-specific T cell repertoire in mice with the apparent tolerant phenotype.
Spleen cells from mice preinjected with RTA:IFA followed by a secondary injection with RTA:CFA exhibited IL-4 and IL-5 production at frequencies characteristic of a single RTA:IFA injection (Fig. 5) . These mice therefore retained the type 2 component induced by the primary IFA treatment; the type 2 cytokine-producing cells were apparently not switched to type 1 producers. The mice secondarily injected with RTA:CFA, however, additionally developed an IFN-␥ component that was considerably reduced in clonal size compared with a primary RTA:CFA immunization (or with control mice primarily injected with PBS:IFA). Additionally, the RTA:IFA-preinjected (protected) mice showed markedly decreased frequencies of IL-2-producing cells compared with those that received primary RTA:CFA injections. Moreover, unlike the control mice, such RTA:IFA-preinjected mice did not engage an IgG2a autoantibody response; the detected serum autoantibodies were of the IgG1 isotype. These data were reproduced essentially identically in the EAE models (MBP in B10.PL and PLPp in SJL mice; not shown). The data are consistent with the primary autoantigen:IFA immunization exhausting the naive/uncommitted T and B cell repertoire. As a consequence, the type 1-biasing secondary immunization with autoantigen:CFA apparently cannot engage the full clonal sizes of the IFN-␥-producing type 1 cells or IgG2a Abs. These data are consistent with a passive tolerance mechanism in which the mice cannot generate or maintain a pathogenic response (thus contributing to their protected state). What they do not explain, however, are the previous reports that showed that IFA-primed cells convey active tolerance when adoptively transferred to naive recipients.
Adoptive transfer of autoantigen:IFA-induced cells suppresses induction of disease, but does not suppress induction of type 1 immunity in the adoptive hosts
We next tested whether transferring spleen cells from autoantigen: IFA-immunized mice into naive recipients could prevent the development of disease upon subsequent immunization with the autoantigen in CFA. Reproducing previously published observations in EAE and ␣TBM disease (4 -6, 50), we found that IFA-induced immunity was in fact transferable to naive recipients (Table III) . As the adoptive recipients have a naive T and B cell repertoire, this model allowed us to examine how the injected regulatory/suppressor cells interfered with the engagement of this naive repertoire by an immunization regimen that would otherwise induce disease. The frequency of IFN-␥ and IL-2 producers in the protected recipients of RTA:IFA-primed cells was comparable with those induced following RTA:CFA immunization of naive mice or mice adoptively transferred with control (MBP:IFA-primed) cells (Fig.  6A) . In contrast to the s.c. primary immunized controls, RTAspecific IL-4 and IL-5 producers were detectable in the recipients of RTA:IFA-primed cells. The adoptive transfer of IFA-primed autoantigen-specific cells did not interfere with the emergence of an IFN-␥-producing, autoantigen-specific memory cell population or with the induction of an IgG2a response (Fig. 6B) . The induction of type 1 immunity seemed, therefore, to be unaffected by the preexistence of type 2 memory cells specific for the same autoantigen.
Discussion
In our first set of experiments, we asked whether i.p. injection of neural or renal autoantigens in IFA, as has been classically done for the prevention of T cell-mediated autoimmune disease, would activate or inactivate the autoantigen-specific T cells. We found that all four of the autoantigens injected in this manner induced CD4 memory cells that produced IL-2 and IL-4 with or without FIGURE 5. Exhaustion of naive precursors in autoantigen:IFA-injected mice. A, Cytokine production by ELISPOT. Groups of mice received primary and (3 wk later) secondary immunizations, as specified. Spleen cells were isolated from groups of mice 16 wk following the secondary immunization and tested for responses to RTA by ELISPOT. Each bar represents the mean value of duplicate RTA-stimulated wells for three to five mice per group after subtraction of spots detected in wells with medium alone. The results are representative of two independent experiments per group. B, RTA-specific IgG1 and IgG2a Abs measured by ELISA in sera of groups of mice specified. Table III IL-5 (but not IFN-␥), consistent with induction of a highly polarized type 2 response (Fig. 1) . These immunizations additionally resulted in the induction of specific IgG1, but not IgG2a Abs (Fig.  3) , further supporting the notion that an immune response, rather than immunologic tolerance, was achieved.
While the overall Ab and cytokine profile of the IFA-induced autoimmune responses corresponded to the classic description of type 2 immunity, it was of interest that with MOG, IL-4 production occurred in the absence of IL-5, while for other autoantigens both IL-4-and IL-5-producing memory cells were induced. Moreover, the frequencies of the individual cells producing either IL-4 or IL-5 did not exactly match. This was true despite the fact that these assays have been optimized so as to measure cytokines produced by individual cells, thus providing accurate frequency measurements (20) . These data are consistent with the newly emerging view that type 1 and type 2 responses are not mediated by classic Th1 or Th2 cells that coexpress the different type 1 or type 2 cytokines in predefined sets (61) . Instead, the data suggest that the production of each cytokine within the type 1 or type 2 response is independently regulated, as has been first noted with in vitro polarized TCR-transgenic cells (62) , and mitogen-stimulated cells (63) (64) (65) . The data are also consistent with the finding that differentiation of IL-4-producing memory cells depends on the presence of IL-4/13, but that of IL-5-producing memory cells is independent of these cytokines (66) . Also, our recent studies of cytokine coexpression in individual in vivo differentiated T cells showed that single cytokine expression seems to be the rule when the T cells were tested directly ex vivo, activated by their physiologic signal, the nominal Ag (20) . In this study, we report the same finding for the IFA-induced T cell responses to autoantigens: IL-4 and IL-5 were produced by different T cells (Fig. 2) . If our observation that regulation of IL-4/5 is under different control mechanisms applies to other type 2 cytokines (i.e., IL-10, IL-6, and TGF-␤), type 2 immunity may not be a uniform response type, but one that occurs in many manifestations. Accordingly, IFA-induced type 2 immunity might differ fundamentally from other type 2 immune responses, e.g., those induced after immunization with Alum (19) or after polarizing T cells in vitro. Some of the controversy on the protective vs pathogenic role of type 2 immunity in autoimmune disease models might result from such diversity within the type 2 immunity studied. This notion about dissociated cytokine expression might be important for understanding type 2 cell-mediated effector and regulatory functions.
CFA is thought to be the strongest adjuvant with which to promote a T cell response in mice (67) . Strikingly, we found that the injections of autoantigens in IFA induced comparable frequencies of cytokine-producing memory T cells (Fig. 1) . The magnitude of the type 2 immunity induced by IFA injections might, therefore, be as strong as can be induced by active immunization (with or without using an adjuvant) or during infection. Despite the strength of the induced autoimmune responses, no pathology was detectable in the target organ, and specifically there was no eosinophilic infiltration as might have been predicted by the high frequency of IL-5-producing autoreactive T cells. As opposed to the injection of large numbers of preactivated Th2 cells, therefore, the active engagement of a cellular type 2 response, even of a most vigorous response, seems to be compatible with health.
The pathogenicity of the autoantibodies induced in association with type 2 immunity has also been a matter of debate. Since the initial studies with IFA-induced tolerance were done with MBP, an intracellular Ag, the lack of Ab-mediated immunopathology might have been due to the lack of access the Abs had to the autoantigen. In contrast, as MOG is a cell surface Ag, evidence arose that autoantibodies associated with type 2 responses might be pathogenic for this Ag (44, 68) . Our experiments using MOG:IFA-injected mice do not point in this direction. Such mice did not exhibit any evidence of clinical EAE (for observations up to several months), and the brains were entirely unaffected upon histologic examination. Nonetheless, the deposition of IgG1 autoantibodies was readily detectable in the brains of such MOG:IFA-immunized mice; the autoantibodies were able to penetrate the BBB and bind to their target cells (Fig. 4) . In the absence of additional T cellmediated inflammation, the exclusion of complement from the CNS and the poor complement-fixing properties of the murine IgG1 Abs (69) may explain the lack of pathogenicity on the CNS exhibited by such autoantibodies. The lack of pathology associated with the massive deposition of Ab in the kidney may further reinforce the notion that the induction of autoantibodies in the mouse can occur without consequence: in the kidney, complement and phagocytes are abundant. It is important to note that our IFA injections in mice induced an autoantibody response void of complement-fixing and Ab-dependent cellular cytotoxicity-mediating IgG2a. It will be of interest to determine whether such polarized (pure) Ab isotype responses are induced by IFA injections in other species (i.e., the rat) in which the pathogenicity of autoantibodies has been described, and in which the observation was made that neuroantigen/IFA injections can cause EAE (46) . Strikingly, in the rat, IgG1 Abs are effective mediators of Ab-dependent cellular cytotoxicity, while they are not good complement fixers (70) . Overall, our data clearly show that, at least in the mouse, the induction of even the most vigorous humoral type 2 autoimmunity is IFA-primed, donor mice as controls (gray bars). Three days later, all animals were immunized with RTA:CFA. Twenty weeks later, the spleen cells of the recipient mice were tested in cytokine ELISPOT recall assays for RTA-induced cytokine production (A), and RTA-specific serum Ab titers were measured (B). As noted in the text, all RTA:IFA-preinjected animals were protected from disease; the other animals developed histologic evidence of interstitial nephritis.
fully compatible with health. The horror autotoxicus (71) may not be so dreadful if a nonpathogenic class (or classes) of autoimmune response(s) is engaged.
The classic observation that preinjection with MBP:IFA protects the host from subsequent induction of MBP:CFA-induced EAE gave rise to the notion that this pretreatment induces tolerance. Because we actually found that vigorous type 2 autoimmunity (not immune tolerance) was induced, we revisited at single cell resolution the autoantigen-specific T cell response in both the originally protected host and in hosts protected by adoptive transfer. We tested whether the preexisting autoantigen-specific type 2 memory cells induced by the IFA immunization would interfere with the induction of a type 1 T cell response when the mice were reinjected with the same autoantigen in CFA. Unlike with naive and control mice, the reinjections of autoantigen in CFA led to a decreased frequency of IFN-␥ and IL-2 producers and did not engage an IgG2a Ab response. These data are consistent with exhaustion of naive precursors, representing a passive tolerance mechanism. Accordingly, the strong primary Ag challenge with IFA might have partially depleted the pool of naive Ag-specific T cells and B cells available for the subsequent induction of a type 1 effector response. In addition, the decreased frequency of IL-2-producing cells in these mice (Fig. 5) , that is, the decreased helper cell function, may deprive the type 1 effector cells from sustaining their clonal sizes and effector function.
Our findings of IFN-␥ production in the absence of IL-2 could alternatively be interpreted as being consistent with T cell anergy in the reinjected mice (72, 73) . Importantly, however, anergy was originally defined in the context of a Th1/Th2 model in which IFN-␥ and IL-2 are produced by the same cell. Because we and others have now demonstrated that IL-2 and IFN-␥ are produced by different CD4 cells (20, 62) , we propose that these results signify exhaustion of IL-2-producing helper cells.
The exhaustion of naive precursor cells and of IL-2-producing helper cells both represent passive tolerance mechanisms that should not be adoptively transferable to a naive recipient. Nevertheless, IFA-induced tolerance is transferable, which demonstrates that there are additional active tolerance mechanisms involved. The recipients of adoptively transferred cells had a naive repertoire available to generate cells producing IL-2 and IFN-␥; yet they were still protected from disease. Although the type 2 component persisted after the reimmunization, it apparently did not interfere with the induction of a type 1 response; thus, the presence of the preprimed type 2 memory cells did not suppress the generation of type 1 cytokine-secreting memory cells, nor did they cause a type 2 shift of the newly engaged response as would be predicted by the guided differentiation model (74, 75) . Guided differentiation predicts that the IL-4 produced by the preexisting Th2 cells would create a type 2 microenvironment when the Ag is reencountered by naive cells, causing them to differentiate along the type 2 pathway as well. The CFA immunizations of mice that received IFA-primed memory cells resulted in frequencies of IFN-␥-secreting T cells that were comparable with immunizations of naive mice, i.e., we found no evidence for type 2 shifting of the naive cells that were induced in the adoptive host (Fig. 6) .
While the fact that the IFA-induced autoreactive T cells adoptively transfer protection fits the classic definition of suppression, we therefore found no evidence that the IFA-induced T cells would actually suppress or otherwise inactivate/deviate de novo T cell responses in the recipient. As an alternative explanation, it is conceivable that the suppressive/regulatory effect of the IFA-induced T cells was not on the effector arm itself, but instead directly on the target organ. For example, subpathogenic immune responses have been shown to cause up-regulation of the antioxidant stress-associated protein hemeoxygenase (HO)-1 in cells of the target organ, rendering these cells resistant to oxidative damage (76), a prerequisite to development of T cell-mediated autoimmune disease (77) . This mechanism has been associated with protection from T cell-mediated inflammatory damage of transplanted organs (76) . Immunohistochemical staining experiments did not, however, reveal up-regulation of HO-1 expression in the target organs of Ag: IFA-immunized mice when compared with naive mice or mice injected with Ag:CFA (both in the MOG:EAE and the ␣TBM disease models; data not shown). Alternatively, classic suppressor cell activity and type 2 cytokine-mediated suppression (e.g., by IL-4, IL-10, TGF-␤) have been implicated in the inactivation of APC function through incapacitating effective Ag presentation as a mechanism of tolerance (30) . When we injected RTA:CFAprimed cells directly under the kidney capsule of RTA:IFA-preinjected mice, however, the cells produced inflammatory lesions comparable with control recipients (data not shown). This finding also argues against significant end-organ resistance.
In summary, while the issue of whether or not the injection of autoantigens in IFA induces clonal inactivation (passive tolerance) or a regulatory response (active tolerance) has been controversial, our utilization of high resolution ELISPOT analysis has permitted us to settle this issue: the injection of autoantigen:IFA induces vigorous immune responses with features of type 2 immunity. The induced tolerant phenotype has features of clonal inactivation because the precursor cells that could give rise to a pathogenic response seem to be converted into memory cells of a nonpathogenic class. Our data also show, however, that the term type 2 immunity does not sufficiently describe the induced immune response. We did not detect classic Th2 cells that coexpress type 2 cytokines as a set, but instead found that the individual Ag-reactive T cells produced these cytokines in a mutually exclusive manner. Moreover, while the IFA-induced cells actively transferred tolerance, no existing model seems sufficient to explain the underlying mechanism. While the exhaustion of naive precursors provides a novel mechanism for passive tolerance, adding to other well-defined pathways, the understanding of active IFA-induced infectious tolerance remains incomplete. An improved comprehension of type 2 immunity per se might be required before we can decipher the mechanisms of active protection afforded by this class of response.
